NL-OMON46049
Completed
Phase 4
A non-interventional biomarker study in patients with NSCLC of adenocarcinoma tumour histology eligible for treatment with Vargatef according to the approved label - Biomarker study in patients with NSCLC
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- lung cancer
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 34
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Women and men with locally advanced, metastatic or locally recurrent NSCLC with histology of adenocarcinoma
- •\- Vargatef is initiated and administered in accordance with the SPC
- •\- Available fixed and paraffin embedded (FPE) tumour tissue routinely obtained at diagnosis and/or re\-biopsy before the initiation of the first line treatment (either block or slides, minimum of 10 slides and up to 20 slides if possible at 5 um thickness).
Exclusion Criteria
- •\- Any contraindication to Vargatef or docetaxel as specified in their respective labels
- •\- Vargatef initiated from more than 7 days prior to inclusion in this NIS
- •\- Patients participating simultaneously in another NIS or a clinical trial
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Clinical research for biomarkers in patients with drug-induced lung injury and their clinical significanceCases of suspected drug-induced lung injury and performed bronchoalveolar lavage for diagnosticJPRN-UMIN000033951niversity of Occupational and Environmental Health, Department of Respiratory Medicine60
Not yet recruiting
Not Applicable
Detection of prognostic biomarkers in patients with oral squamous cell carcinoma with tissue microarrayOral Squamous Cell CarcinomaC01C02C03C04C05C06Malignant neoplasm of base of tongueMalignant neoplasm of other and unspecified parts of tongueMalignant neoplasm of gumMalignant neoplasm of floor of mouthMalignant neoplasm of palateMalignant neoplasm of other and unspecified parts of mouthDRKS00010431niversitätsklinikum Hamburg-Eppendorf1,000
Completed
Not Applicable
Investigations on biomarker search in patients with bronchial carcinoma under antibody (checkpoint blockade) therapyC34.9Bronchus or lung, unspecifiedDRKS00022872Krankenhaus Martha-Maria Halle-Dölau30
Completed
Not Applicable
Investigations on biomarker search in patients with non-small-cell bronchial carcinoma under checkpoint inhibitor therapyC34.9Bronchus or lung, unspecifiedDRKS00022767Krankenhaus Martha-Maria Halle-Dölau92
Recruiting
Not Applicable
Pilot study: clinical evaluation of biomarkers as predictors of survival in castrate-resistant prostate cancer patients.NL-OMON34838niversitair Medisch Centrum Sint Radboud50